SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

Emvistegrast

GILD·GILEAD SCIENCES, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2
Time to market
If Phase 3 begins in 2027, a typical 12-18 month enrollment and follow-up period would put Phase 3 readout around 2028-2029, with potential FDA filing around 2029-2030 at the earliest, assuming positive results.
Why 4/10
Emvistegrast is a Phase 2 drug whose next hard catalyst (Phase 3 topline readout) is likely more than 12 months away, and it represents a small part of Gilead's large, diversified pipeline (HIV, oncology, liver disease). The Phase 2 data was already released on October 19, 2026, so no upcoming binary event is scheduled within the next ~12 months.
Actionable Insight NEUTRAL

The Phase 2 data is now public (October 19, 2026). The next catalyst is the planned Phase 3 monotherapy study initiation in 2027, which is not a hard binary event. Investors should watch for the Phase 3 trial design details, enrollment timelines, and any expansion into Crohn's disease or combination regimens. The key competitive watchpoints are Eli Lilly's oral alpha4/beta7 inhibitor zotemtegrast (Phase 2) and Takeda's Entyvio franchise facing biosimilar erosion.

Price Chart

Loading chart...

Executive Summary

Emvistegrast (GS-1427) is Gilead Sciences' investigational once-daily oral pill for moderate to severe ulcerative colitis. It works by blocking the alpha4/beta7 integrin pathway, the same clinically validated target as Takeda's blockbuster injectable Entyvio (vedolizumab), but in an oral format. On October 19, 2026, Gilead reported positive Phase 2 SWIFT trial results: the 200mg dose achieved 66% clinical response and 31% clinical remission at 12 weeks versus 37% and 8% for placebo, respectively. The drug was generally well tolerated. Gilead plans to start a Phase 3 monotherapy study in 2027. For a large-cap diversified biotech like Gilead, emvistegrast is an important pipeline asset but not a near-term binary catalyst.

How It Works

Emvistegrast is an oral small-molecule pill that blocks the alpha4/beta7 integrin, a protein on the surface of certain immune cells that acts like a homing beacon directing those cells to the gut. By blocking this beacon, the drug prevents inflammatory immune cells from entering intestinal tissue, reducing the chronic inflammation that causes ulcerative colitis symptoms. This is the same mechanism as the injected drug Entyvio (vedolizumab), but delivered as a convenient once-daily pill.

Trial Status

The Phase 2 SWIFT dose-ranging study (NCT06290934) enrolled 238 adults with moderately to severely active ulcerative colitis across four arms (200mg, 75mg, 25mg emvistegrast, or placebo). The 12-week induction phase met its primary endpoint, with the 200mg dose showing 66% clinical response versus 37% for placebo (nominal p<0.001). Clinical remission was 31% versus 8%. Results were presented as a late-breaking abstract at UEGW 2026 in Barcelona. Longer-term safety and maintenance data are still being collected. Gilead plans to initiate a Phase 3 monotherapy study in 2027.

The Two-Sided Case

▲ Bull Case5
Phase 2 data showed strong efficacy: 66% clinical response and 31% remission at 12 weeks with 200mg dose, both statistically significant versus placebo
Oral once-daily formulation offers major convenience advantage over injectable Entyvio, which requires IV infusion, potentially expanding the treatable patient population
Cross-trial comparison suggests emvistegrast's 31% remission rate may exceed Entyvio's ~17% remission rate in its Phase 3 trials
Targets a clinically validated pathway (alpha4/beta7 integrin) with a well-established safety profile from the Entyvio class
Analysts at BMO Capital Markets called the data 'highly competitive' and said it validates Gilead's push into immunology and inflammation beyond HIV
▼ Bear Case5
Emvistegrast is still early-stage (Phase 2); Phase 3 trials can fail even after promising Phase 2 results
Competition is intensifying: Eli Lilly's oral alpha4/beta7 inhibitor zotemtegrast (formerly MORF-057) is also in Phase 2 development for UC
Longer-term safety and maintenance data are not yet available; the Phase 2 study only covered 12 weeks of induction
Gilead is a late entrant to the IBD space, competing against entrenched players like Takeda (Entyvio), AbbVie (Skyrizi, Rinvoq), and Johnson & Johnson (Stelara, Tremfya)
As a small part of Gilead's large diversified portfolio, even a successful emvistegrast launch would have limited impact on the overall stock price

Upcoming Catalysts

  • Phase 3 monotherapy study initiation (planned for 2027)
  • Long-term safety and maintenance data from SWIFT extension
  • Potential expansion into Crohn's disease or combination regimens

Source Filing

The SecBot filing or press-release report that triggered this drug report:

GILEAD SCIENCES, INC. 8-K GILD ·Originating report

Sources · 12

Hover a chip for the title
1 gilead.com2 en.wikipedia.org3 reuters.com4 fiercebiotech.com5 biospace.com6 statnews.com7 drughunter.com8 pharmashots.com9 endpoints.news10 thepharmaletter.com11 clinicaltrials.gov12 sec.gov